Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1980;68(2):139-46.
doi: 10.1007/BF00432131.

Differential behavioral and biochemical effects of four dopaminergic agonists

Comparative Study

Differential behavioral and biochemical effects of four dopaminergic agonists

G Gianutsos et al. Psychopharmacology (Berl). 1980.

Abstract

Some behavioral and biochemical effects of four dopaminergic agonists (apomorphine, piribedil, lergotrile, and bromocriptine) were determined in the mouse. As expected, all four drugs dose-dependently reversed the alpha-methyltyrosine-induced decline of forebrain dopamine. All four compounds reduced locomotor activity at low doses, but only apomorphine and bromocriptine increased motor activity at higher doses. All four drugs caused some reversal of the baclofen-induced elevation in forebrain dopamine concentrations, but only apomorphine and bromocriptine completely reversed the effects of baclofen. After chronic treatment with haloperidol, the behavioral effects of lergotrile and bromocriptine were altered. Doses of those drugs reducing motor activity in normal animals were ineffective after chronic haloperidol. The latent stimulation induced by bromocriptine was enhanced, while a stimulatory effect of lergotrile emerged in these animals. These effects were noted in conjunction with an enhanced sensitivity to the drug-induced decrease in dopamine turnover. These results demonstrate that dopamine agonists may be differentiated on the basis of certain behavioral and biochemical tests and suggest an interaction of these drugs with two different populations of dopamine receptors.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Adv Biochem Psychopharmacol. 1977;16:251-6 - PubMed
    1. Pharmacology. 1978;16 Suppl 1:143-9 - PubMed
    1. Neuropharmacology. 1978 Mar;17(3):169-74 - PubMed
    1. Eur J Pharmacol. 1972 Nov;20(2):195-204 - PubMed
    1. Psychopharmacologia. 1976 Feb 2;45(3):243-54 - PubMed

Publication types

LinkOut - more resources